NUP210 and primary biliary cholangitis: Moreover, 26 (96.3%) out of the 27 PBC-patients were EUROLINE immunoblot-positive; AMA-M2 (n = 22, 81.5%), anti-BPO (n = 24, 88.9%), anti-Sp100 (n = 8, 29.6%), anti-gp210 (n = 5, 18.5%), and anti-PML (n = 2, 7.4%)—see Figure 3 and Table 2.